Regenxbio Inc
NASDAQ:RGNX

Watchlist Manager
Regenxbio Inc Logo
Regenxbio Inc
NASDAQ:RGNX
Watchlist
Price: 8.54 USD -0.23% Market Closed
Market Cap: 428.4m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

RGNX Price Targets Summary
Regenxbio Inc

Wall Street analysts forecast RGNX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RGNX is 32.39 USD with a low forecast of 13.13 USD and a high forecast of 54.6 USD.

RGNX Lowest Forecast
Wall Street Target
13.13 USD
54% Upside
RGNX Average Forecast
Wall Street Target
32.39 USD
279% Upside
RGNX Highest Forecast
Wall Street Target
54.6 USD
539% Upside
Lowest
Price Target
13.13 USD
54% Upside
Average
Price Target
32.39 USD
279% Upside
Highest
Price Target
54.6 USD
539% Upside
Regenxbio Inc Competitors:
Price Targets
1167
Jacobio Pharmaceuticals Group Co Ltd
57% Downside
GLPG
Galapagos NV
26% Upside
ACAD
ACADIA Pharmaceuticals Inc
22% Upside
MDXG
MiMedx Group Inc
105% Upside
1167
Jacobio Pharmaceuticals Group Co Ltd
57% Downside
GLPG
Galapagos NV
26% Upside
ACAD
ACADIA Pharmaceuticals Inc
22% Upside
MDXG
MiMedx Group Inc
105% Upside
MIRM
Mirum Pharmaceuticals Inc
43% Upside
TSHA
Taysha Gene Therapies Inc
229% Upside
ITOS
Iteos Therapeutics Inc
19% Upside
RCUS
Arcus Biosciences Inc
233% Upside

Revenue
Forecast

Revenue Estimate
Regenxbio Inc

For the last 8 years the compound annual growth rate for Regenxbio Inc's revenue is 44%. The projected CAGR for the next 3 years is 59%.

44%
Past Growth
59%
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Regenxbio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Regenxbio Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

See Also

Summary
RGNX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RGNX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RGNX stock valuation using valuation multiples.
Wall Street Estimates
RGNX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RGNX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RGNX's stock price target?
Price Target
32.39 USD

According to Wall Street analysts, the average 1-year price target for RGNX is 32.39 USD with a low forecast of 13.13 USD and a high forecast of 54.6 USD.

What is Regenxbio Inc's Revenue forecast?
Projected CAGR
59%

For the last 8 years the compound annual growth rate for Regenxbio Inc's revenue is 44%. The projected CAGR for the next 3 years is 59%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.